Download PDF
Facial Plast Surg 2022; 38(02): 111-115
DOI: 10.1055/s-0041-1741531
Original Article

Botulinum Toxin Type A: Adverse Events and Management

Maurizio Cavallini
1   Operative Unit of Dermatology and Dermato-Surgery, Centro Diagnostico Italiano Hospital, Milan, Italy
,
Marco Papagni
2   Italian Scientific Society of Aesthetic Medicine, Milan, Italy
,
Riccardo Lazzari
2   Italian Scientific Society of Aesthetic Medicine, Milan, Italy
,
Adriano Santorelli
3   Academy of Aesthetic Sciences, Naples, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Aesthetic medicine is witnessing an increasing exploitation of all the procedures. The demand has never been higher than it is today. The number of practitioners is also increasing year by year. Consequently complications and other kinds of related troubles and procedures are also rising. Never like today is fundamental, in case of troubles, how to properly manage with the most frequent issues. In aesthetic medicine field, botulinum toxin procedures are the safest. Lot of patients are worried about botulinum toxin despite the available scientific literature. Rare short-term complications are observed. In the most of cases, nothing severe occurs if the international recommendations and the most recent guidelines are closely followed, the majority of them are injection related. This study is a review of rare or common problems that can occur and how to manage or solve the situations.

Keywords

botulinum toxin - depressor anguli oris - adverse events - safety - Onabotulinum toxin-A


Publication History

Article published online:
07 February 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Dover JS, Monheit G, Greener M, Pickett A. Botulinum toxin in aesthetic medicine: myths and realities. Dermatol Surg 2018; 44 (02) 249-260
    CrossrefPubMedGoogle Scholar
  • 2 Park MY, Ahn KY. Scientific review of the aesthetic uses of botulinum toxin type A. Arch Craniofac Surg 2021; 22 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 3 Zargaran D, Zoller FE, Zargaran A, Mosahebi A. Complications of facial cosmetic botulinum toxin A injection: analysis of the UK Medicines & Healthcare Products Regulatory Agency registry and literature review. J Plast Reconstr Aesthet Surg 2021; Jun 17; S1748-6815 (21) 00332-00336
    PubMedGoogle Scholar
  • 4 Kroumpouzos G, Kassir M, Gupta M, Patil A, Goldust M. Complications of botulinum toxin a: an update review. J Cosmet Dermatol 2021; 20 (06) 1585-1590
    CrossrefPubMedGoogle Scholar
  • 5 Sethi N, Singh S, DeBoulle K, Rahman E. A review of complications due to the use of botulinum toxin A for cosmetic indications. Aesthetic Plast Surg 2021; 45 (03) 1210-1220
    CrossrefPubMedGoogle Scholar
  • 6 Tian X, Gao L, Fu G. et al. A rare case of severe systemic life-threatening botulism caused by a local botulinum toxin-A injection. JAAD Case Rep 2020; 6 (09) 854-857
    CrossrefPubMedGoogle Scholar
  • 7 Chertow DS, Tan ET, Maslanka SE. et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006; 296 (20) 2476-2479
    CrossrefPubMedGoogle Scholar
  • 8 Fan KL, Wang YL, Chu G, Leung LP. Delayed antitoxin treatment of two adult patients with botulism after cosmetic injection of botulinum type A toxin. J Emerg Med 2016; 51 (06) 677-679
    CrossrefPubMedGoogle Scholar
  • 9 Foissac R, Benatar MJ. Influence of botulinum toxin type A esthetic injections on facial expressions. J Cosmet Dermatol 2021; 20 (05) 1405-1410
    CrossrefPubMedGoogle Scholar
  • 10 Raspaldo H, Baspeyras M, Bellity P. et al; Consensus Group. Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus—part 1. J Cosmet Dermatol 2011; 10 (01) 36-50
    CrossrefPubMedGoogle Scholar
  • 11 Lorenc ZP, Kenkel JM, Fagien S. et al. Consensus panel's assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics. Aesthet Surg J 2013; 33 (suppl I): 35S-40S
    CrossrefPubMedGoogle Scholar
  • 12 Krasilnikova O, Pozdnyakova M. Innovative approach to aesthetical medicine services quality assessment. J Cosmet Dermatol 2021; 20 (02) 636-646
    CrossrefPubMedGoogle Scholar
  • 13 Bertossi D, Cavallini M, Cirillo P. et al. Italian consensus report on the aesthetic use of onabotulinum toxin A. J Cosmet Dermatol 2018; 17 (05) 719-730
    CrossrefPubMedGoogle Scholar
  • 14 Borba A, Matayoshi S, Rodrigues M. Avoiding complications on the upper face treatment with botulinum toxin: a practical guide. Aesthetic Plast Surg 2022; 46 (01) 385-394
    CrossrefPubMedGoogle Scholar
  • 15 Hexsel D, Brum C, do Prado DZ. et al. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 2012; 67 (02) 226-232
    CrossrefPubMedGoogle Scholar
  • 16 Kranz G, Haubenberger D, Voller B. et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 2009; 24 (02) 231-236
    CrossrefPubMedGoogle Scholar
  • 17 Renga M. A personalized treatment approach of frontalis muscle with botulinum toxin A (Bont-A) related to functional anatomy: case studies. J Cosmet Laser Ther 2020; 22 (02) 100-106
    CrossrefPubMedGoogle Scholar
  • 18 Angelo-Khattar M. A novel onabotulinumtoxin A treatment technique to obtain predictable outcomes in eyebrow position and shape. Clin Cosmet Investig Dermatol 2020; 13: 781-787
    CrossrefPubMedGoogle Scholar
  • 19 Nagendran ST, Ali MJ, Dogru M, Malhotra R. Complications and adverse effects of periocular aesthetic treatments. Surv Ophthalmol 2021; DOI: 10.1016/j.survophthal.2021.04.009.
    CrossrefPubMedGoogle Scholar
  • 20 Raveendran SS, Anthony DJ. Classification and morphological variation of the frontalis muscle and implications on the clinical practice. Aesthetic Plast Surg 2021; 45 (01) 164-170
    CrossrefPubMedGoogle Scholar
  • 21 Du YX, Wu L, Shen Y. Advances in iatrogenic eye complications caused by facial cosmetic injections. Zhonghua Yan Ke Za Zhi 2021; 57 (05) 391-395
    PubMedGoogle Scholar
  • 22 Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with apraclonidine. J Neurol Sci 2017; 372: 57-59
    CrossrefPubMedGoogle Scholar
  • 23 Heydenrych I. The treatment of facial asymmetry with botulinum toxin: current concepts, guidelines, and future trends. Indian J Plast Surg 2020; 53 (02) 219-229
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Witmanowski H, Błochowiak K. The whole truth about botulinum toxin—a review. Postepy Dermatol Alergol 2020; 37 (06) 853-861
    CrossrefPubMedGoogle Scholar
  • 25 Kutschenko A, Weisemann J, Kollewe K. et al. Botulinum neurotoxin serotype D—a potential treatment alternative for BoNT/A and B non-responding patients. Clin Neurophysiol 2019; 130 (06) 1066-1073
    CrossrefPubMedGoogle Scholar
  • 26 Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel) 2019; 11 (09) 491
    CrossrefPubMedGoogle Scholar
  • 27 de Maio M, DeBoulle K, Braz A, Rohrich RJ. Alliance for the Future of Aesthetics Consensus Committee. Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the midface. Plast Reconstr Surg 2017; 140 (04) 540e-550e
    CrossrefPubMedGoogle Scholar
  • 28 Chang YS, Chang CC, Shen JH, Chen YT, Chan KK. Nonallergic eyelid edema after botulinum toxin type a injection: case report and review of literature. Medicine (Baltimore) 2015; 94 (38) e1610
    CrossrefPubMedGoogle Scholar
  • 29 Auada Souto MP, Souto LRM. An unusual adverse event of botulinum toxin injection in the lower face. J Cosmet Dermatol 2021; 20 (05) 1381-1384
    CrossrefPubMedGoogle Scholar
  • 30 Gong X, Huang H, Gu C. et al. Individual factors of botulinum type A in treatment of gummy smile: a prospective study. Aesthet Surg J 2021; 41 (07) NP842-NP850
    CrossrefPubMedGoogle Scholar
  • 31 Li Y, Chong Y, Yu N, Dong R, Long X. The use of botulinum toxin A in upper lip augmentation. J Cosmet Dermatol 2021; 20 (01) 71-74
    CrossrefPubMedGoogle Scholar
  • 32 Yeh YT, Peng JH, Peng HP. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy. J Cosmet Dermatol 2018; 17 (05) 675-687
    CrossrefPubMedGoogle Scholar
  • 33 Bae H, Kim J, Seo KK, Hu KS, Kim ST, Kim HJ. Comparison between conventional blind injections and ultrasound-guided injections of botulinum toxin type A into the masseter: a clinical trial. Toxins (Basel) 2020; 12 (09) 588
    CrossrefPubMedGoogle Scholar